Tumor Angiogenesis

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2008 May 9

PMID 18463380

Citations 990

Authors

Robert S Kerbel

Affiliations

Soon will be listed here.

Citing Articles

Critical roles of miR-21 in promotions angiogenesis: friend or foe?.

Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S Clin Exp Med. 2025; 25(1):66.

PMID: 39998742 PMC: 11861128. DOI: 10.1007/s10238-025-01600-7.

Matrix Stiffness-Mediated DNA Methylation in Endothelial Cells.

Taufalele P, Kirkham H, Reinhart-King C Cell Mol Bioeng. 2025; 18(1):29-38.

PMID: 39949487 PMC: 11813852. DOI: 10.1007/s12195-024-00836-9.

Type IV collagen derived non-collagenous domain α6 (IV) NC1 and its derivative fragments inhibit endothelial cell proliferation and attenuates chorioallantoic membrane angiogenesis.

Setti A, Pasha A, Makani V, Bhadra M, Pawar S Cytotechnology. 2025; 77(2):47.

PMID: 39867830 PMC: 11759748. DOI: 10.1007/s10616-025-00709-7.

Antiangiogenic therapy exerts antitumor effects by altering the tumor microenvironment: bibliometric analysis.

Kang Y, Kang Y, Zhang D, Yao J Front Immunol. 2024; 15:1460533.

PMID: 39691714 PMC: 11649635. DOI: 10.3389/fimmu.2024.1460533.

Targeting Radiation Resistance in Oesophageal Adenocarcinoma with Pyrazinib-Functionalised Gold Nanoparticles.

Marcone S, Spadavecchia J, Khan M, Vella G, OConnell F, Pendino M Cancers (Basel). 2024; 16(23).

PMID: 39682192 PMC: 11640662. DOI: 10.3390/cancers16234007.

References

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Kerbel R, Folkman J . Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2(10):727-39. DOI: 10.1038/nrc905. View

Mancuso M, Davis R, Norberg S, OBrien S, Sennino B, Nakahara T . Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006; 116(10):2610-21. PMC: 1578604. DOI: 10.1172/JCI24612. View

Fukumura D, Xavier R, Sugiura T, Chen Y, Park E, Lu N . Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998; 94(6):715-25. DOI: 10.1016/s0092-8674(00)81731-6. View

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

Kerbel R, Kamen B . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-36. DOI: 10.1038/nrc1369. View

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

Thurston G, Noguera-Troise I, Yancopoulos G . The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7(5):327-31. DOI: 10.1038/nrc2130. View

10.

Gerber H, Malik A, Solar G, Sherman D, Liang X, Meng G . VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002; 417(6892):954-8. DOI: 10.1038/nature00821. View

11.

Ebos J, Lee C, Christensen J, Mutsaers A, Kerbel R . Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104(43):17069-74. PMC: 2040401. DOI: 10.1073/pnas.0708148104. View

12.

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

13.

Shaked Y, Ciarrocchi A, Franco M, Lee C, Man S, Cheung A . Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313(5794):1785-7. DOI: 10.1126/science.1127592. View

14.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

15.

Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M . Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2005; 18(1):1-9. DOI: 10.1093/intimm/dxh334. View

16.

Lobov I, Renard R, Papadopoulos N, Gale N, Thurston G, Yancopoulos G . Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007; 104(9):3219-24. PMC: 1805530. DOI: 10.1073/pnas.0611206104. View

17.

Tozer G, Kanthou C, Baguley B . Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5(6):423-35. DOI: 10.1038/nrc1628. View

18.

Hanahan D . Signaling vascular morphogenesis and maintenance. Science. 1997; 277(5322):48-50. DOI: 10.1126/science.277.5322.48. View

19.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T . Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-7. DOI: 10.1126/science.275.5302.964. View

20.

Berenson A . A cancer drug shows promise, at a price that many can't pay. N Y Times Web. 2006; :A1, C2. View